Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14072306 | 1.00 | CA2 (0.30) | CA2 | |
| SCHEMBL11114168 | 0.81 | CA2 (0.33) | CA2 | |
| SCHEMBL28595771 | 0.81 | CA2 (0.33) | CA2 | |
| SCHEMBL14072280 | 0.78 | — | — | |
| SCHEMBL14627155 | 0.78 | — | — | |
| SCHEMBL10918019 | 0.78 | CA2 (0.33) | CA2 | |
| SCHEMBL14064541 | 0.78 | — | — | |
| SCHEMBL14072307 | 0.78 | — | — | |
| SCHEMBL15445567 | 0.70 | CA2 (0.32) | CA2 | |
| SCHEMBL24543316 | 0.70 | CA2 (0.33) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010022148-A1 | METHODS FOR THE PREPARATION OF IRCINIASTATIN AND ANALOGS THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-02-25 | — | — | WO | disclosed |
| US-7429616-B2 | Synthesis and complete stereochemical assignment of psymberin/irciniastatin for use as antitumor compounds | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2008-09-30 | — | — | US | disclosed |
| WO-2007011629-A2 | SYNTHESIS AND COMPLETE STEREOCHEMICAL ASSIGNMENT OF PSYMBERIN/IRCINIASTATIN FOR ANTI-TUMOR USE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2007-01-25 | — | — | WO | disclosed |
| US-20070015821-A1 | Synthesis and complete stereochemical assignment of psymberin/irciniastatin for use as antitumor compounds | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM | 2007-01-18 | — | — | US | disclosed |
| US-20070015821-A1 | Synthesis and complete stereochemical assignment of psymberin/irciniastatin for use as antitumor compounds | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015821-A1 | Synthesis and complete stereochemical assignment of psymberin/irciniastatin for use as antitumor compounds | HCCS, RPS24, RPS27 | CA2 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.